These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37245700)

  • 1. Trials using composite outcomes neglect the presence of competing risks: a methodological survey of cardiovascular studies.
    Kim H; Shahbal H; Parpia S; Averbuch T; Van Spall HGC; Thabane L; Ma J
    J Clin Epidemiol; 2023 Aug; 160():1-13. PubMed ID: 37245700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Communicating and understanding statistical measures when quantifying the between-group difference in competing risks.
    Wu H; Zhang C; Hou Y; Chen Z
    Int J Epidemiol; 2023 Dec; 52(6):1975-1983. PubMed ID: 37738672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Criteria for use of composite end points for competing risks-a systematic survey of the literature with recommendations.
    Manja V; AlBashir S; Guyatt G
    J Clin Epidemiol; 2017 Feb; 82():4-11. PubMed ID: 27965044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the Absolute Risk of Cardiovascular Disease and Other Events: Issues With the Use of Multiple Fine-Gray Subdistribution Hazard Models.
    Austin PC; Putter H; Lee DS; Steyerberg EW
    Circ Cardiovasc Qual Outcomes; 2022 Feb; 15(2):e008368. PubMed ID: 35098725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models.
    Mozumder SI; Rutherford MJ; Lambert PC
    BMC Med Res Methodol; 2021 Mar; 21(1):52. PubMed ID: 33706711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation and modeling of the restricted mean time lost in the presence of competing risks.
    Conner SC; Trinquart L
    Stat Med; 2021 Apr; 40(9):2177-2196. PubMed ID: 33567477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculations in the presence of competing risks.
    Latouche A; Porcher R
    Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Health and Cardiovascular Disease: Mapping Clinical Heterogeneity and Methodological Gaps.
    Aldossri M; Farmer J; Saarela O; Rosella L; Quiñonez C
    JDR Clin Trans Res; 2021 Oct; 6(4):390-401. PubMed ID: 32886582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
    Tai BC; Chen ZJ; Machin D
    Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The number of primary events per variable affects estimation of the subdistribution hazard competing risks model.
    Austin PC; Allignol A; Fine JP
    J Clin Epidemiol; 2017 Mar; 83():75-84. PubMed ID: 28088594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of pathogen-specific clinical mastitis in the first 100 days of first lactation with productive lifetime: An observational study comparing competing risks models for death and sale with the Cox model.
    Hertl JA; Schukken YH; Tauer LW; Welcome FL; Gröhn YT
    Prev Vet Med; 2023 Apr; 213():105879. PubMed ID: 36841041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin C supplementation for the primary prevention of cardiovascular disease.
    Al-Khudairy L; Flowers N; Wheelhouse R; Ghannam O; Hartley L; Stranges S; Rees K
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011114. PubMed ID: 28301692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost.
    Wu H; Yuan H; Yang Z; Hou Y; Chen Z
    Am J Epidemiol; 2022 Jan; 191(1):163-172. PubMed ID: 34550319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Qigong for the primary prevention of cardiovascular disease.
    Hartley L; Lee MS; Kwong JS; Flowers N; Todkill D; Ernst E; Rees K
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD010390. PubMed ID: 26068956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks.
    Yang Q; Fung WK; Li G
    Stat Med; 2018 Apr; 37(8):1389-1401. PubMed ID: 29282764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry.
    Lau B; Cole SR; Gange SJ
    Stat Med; 2011 Mar; 30(6):654-65. PubMed ID: 21337360
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.